CN106687581A - 用于治疗用途的岩藻糖基化细胞的制备和冷冻干燥 - Google Patents

用于治疗用途的岩藻糖基化细胞的制备和冷冻干燥 Download PDF

Info

Publication number
CN106687581A
CN106687581A CN201580036891.9A CN201580036891A CN106687581A CN 106687581 A CN106687581 A CN 106687581A CN 201580036891 A CN201580036891 A CN 201580036891A CN 106687581 A CN106687581 A CN 106687581A
Authority
CN
China
Prior art keywords
cells
cell
therapeutic cells
fucosylation
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580036891.9A
Other languages
English (en)
Chinese (zh)
Inventor
S·D·沃尔夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Targazyme Inc
Original Assignee
Targazyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targazyme Inc filed Critical Targazyme Inc
Priority to CN202210090681.XA priority Critical patent/CN114540266A/zh
Publication of CN106687581A publication Critical patent/CN106687581A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0006—Modification of the membrane of cells, e.g. cell decoration
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/16—Physical preservation processes
    • A01N1/162—Temperature processes, e.g. following predefined temperature changes over time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01065—3-Galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase (2.4.1.65), i.e. alpha-1-3 fucosyltransferase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/724—Glycosyltransferases (EC 2.4.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Materials For Medical Uses (AREA)
CN201580036891.9A 2014-07-07 2015-07-07 用于治疗用途的岩藻糖基化细胞的制备和冷冻干燥 Pending CN106687581A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210090681.XA CN114540266A (zh) 2014-07-07 2015-07-07 用于治疗用途的岩藻糖基化细胞的制备和冷冻干燥

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462021328P 2014-07-07 2014-07-07
US62/021,328 2014-07-07
PCT/US2015/039370 WO2016007506A1 (en) 2014-07-07 2015-07-07 Manufacture and cryopreservation of fucosylated cells for therapeutic use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210090681.XA Division CN114540266A (zh) 2014-07-07 2015-07-07 用于治疗用途的岩藻糖基化细胞的制备和冷冻干燥

Publications (1)

Publication Number Publication Date
CN106687581A true CN106687581A (zh) 2017-05-17

Family

ID=55064767

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580036891.9A Pending CN106687581A (zh) 2014-07-07 2015-07-07 用于治疗用途的岩藻糖基化细胞的制备和冷冻干燥
CN202210090681.XA Pending CN114540266A (zh) 2014-07-07 2015-07-07 用于治疗用途的岩藻糖基化细胞的制备和冷冻干燥

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210090681.XA Pending CN114540266A (zh) 2014-07-07 2015-07-07 用于治疗用途的岩藻糖基化细胞的制备和冷冻干燥

Country Status (9)

Country Link
US (3) US20170121673A1 (https=)
EP (1) EP3167046A4 (https=)
JP (3) JP2017525340A (https=)
KR (1) KR102505009B1 (https=)
CN (2) CN106687581A (https=)
AU (2) AU2015288052B2 (https=)
CA (1) CA2954534C (https=)
SG (1) SG11201610699XA (https=)
WO (1) WO2016007506A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113521249A (zh) * 2020-04-14 2021-10-22 慈济学校财团法人慈济大学 动员干细胞的方法
CN114615886A (zh) * 2019-08-29 2022-06-10 得克萨斯大学体系董事会 细胞冷冻保存培养基

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7332334B2 (en) 2003-04-18 2008-02-19 Oklahoma Medical Research Foundation Hematopoietic stem cells treated by in vitro fucosylation and methods of use
US20140161782A1 (en) 2008-06-09 2014-06-12 Targazyme, Inc. Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucoslytransferase
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
JP6493692B2 (ja) 2013-03-15 2019-04-10 セルジーン コーポレイション 修飾されたｔリンパ球
CA2954534C (en) * 2014-07-07 2023-04-04 Targazyme, Inc. Manufacture and cryopreservation of fucosylated cells for therapeutic use
SG11201705401YA (en) * 2014-12-30 2017-08-30 The Brigham And Women`S Hospital Inc Methods to improve cell therapy
IL309689B1 (en) * 2017-02-28 2026-02-01 Univ Central Florida Res Found Inc PM21 particles to enhance NK cell migration to the bone marrow
CN108617638B (zh) * 2017-03-22 2020-01-24 拜西欧斯（北京）生物技术有限公司 组织和/或细胞冻存保护液及其制备与应用
CN108925548A (zh) * 2017-05-24 2018-12-04 西比曼生物科技（香港）有限公司 一种冻存细胞制剂及细胞复苏方式
CN107012119B (zh) * 2017-05-31 2020-03-17 东莞市保莱生物科技有限公司 一种从骨髓中提取免疫细胞的方法
IL276365B2 (en) 2018-02-01 2023-10-01 Nkmax Co Ltd A method for the production of natural killer cells and a preparation for cancer treatment
CN108404219B (zh) * 2018-02-11 2020-09-29 华中科技大学 一种基于冷冻铸造技术的小口径人工血管及其制备方法
CN112135901A (zh) * 2018-03-01 2020-12-25 格雷戈里奥马拉尼翁医院生物医学研究基金会 获得源自胸腺组织的调节性t细胞的方法及所述细胞作为细胞免疫疗法在免疫系统失调中的用途
WO2019226618A1 (en) * 2018-05-22 2019-11-28 Nantkwest, Inc. Methods and systems for cell bed formation during bioprocessing
JP7072147B2 (ja) * 2018-09-13 2022-05-20 極東製薬工業株式会社 間葉系幹細胞の凍害保護液とその利用
CN114929249A (zh) * 2019-11-29 2022-08-19 Nkmax有限公司 产生自然杀伤细胞及其组合物的方法
CN112913832A (zh) * 2021-01-27 2021-06-08 河南省华隆生物技术有限公司 一种滋养层细胞的保存方法
EP4316498A4 (en) 2021-03-30 2025-03-26 Kaneka Corporation Trypsin inhibition method, and method for producing cell preparation in which same is used
JP2022159210A (ja) * 2021-03-31 2022-10-17 株式会社カネカ 凍結接着性幹細胞の製造方法
CN113151163A (zh) * 2021-04-23 2021-07-23 优牙生物科技(上海)有限公司 一种使用牙髓干细胞制剂修复子宫内膜损伤的方法
CN113396894A (zh) * 2021-07-06 2021-09-17 南方医科大学南方医院 适用于单位毛囊保存的复合冻存液及其制备方法和应用
CN116649328A (zh) * 2023-05-10 2023-08-29 杭州中赢生物医疗科技有限公司 一种人类活性免疫细胞冻存液及其冻存方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039104A1 (en) * 1996-04-17 1997-10-23 Osiris Therapeutics, Inc. Cryopreservation and extensive subculturing of human mesenchymal stem cells
US20040209357A1 (en) * 2003-04-18 2004-10-21 Lijun Xia Hematopoietic stem cells treated by in vitro fucosylation and methods of use
US20050026133A1 (en) * 2002-01-31 2005-02-03 Asahi Techno Glass Corporation Cryopreservation medium for primate embryo stem cells and cryopreservation method
WO2005017115A3 (en) * 2003-08-11 2005-06-02 Sinai School Medicine Cord blood-derived hematopoietic progenitor cells
US20100304436A1 (en) * 2009-06-02 2010-12-02 Regeneron Pharmaceuticals, Inc. Fucosylation-Deficient Cells
US20100311036A1 (en) * 2009-06-09 2010-12-09 University Of South Carolina Methods for Augmentation of Cell Cryopreservation
US20110091434A1 (en) * 2008-06-09 2011-04-21 America Stem Cell, Inc. Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucosyltransferase
US20110136682A1 (en) * 2009-12-04 2011-06-09 Momenta Pharmaceuticals, Inc. Antennary fucosylation in glycoproteins from cho cells
CN102648708A (zh) * 2011-02-25 2012-08-29 深圳华大方舟生物技术有限公司 一种用于胚胎或细胞的冷冻液及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789147A (en) 1994-12-05 1998-08-04 New York Blood Center, Inc. Method for concentrating white cells from whole blood by adding a red cell sedimentation reagent to whole anticoagulated blood
AU8005098A (en) 1997-06-06 1998-12-21 Governors Of The University Of Alberta, The Alpha1,3-fucosyltransferase of helicobacter pylori
US6461835B1 (en) 1998-09-03 2002-10-08 The University Of Oklahoma Fucosyltransferases, polynucleotides encoding fucosyltransferases, and transgenic mammal incorporating same
US20060210558A1 (en) 2000-10-18 2006-09-21 Robert Sackstein Hematopoietic cell selectin ligand polypeptides and methods of use thereof
CA2431901A1 (en) * 2000-12-14 2002-06-20 The University Of British Columbia Crystal structures of retaining glycosyltransferases
US20100143969A1 (en) * 2005-03-24 2010-06-10 Neose Technologies, Inc. Expression of soluble, active eukaryotic glycosyltransferases in prokaryotic organisms
JP2008539796A (ja) * 2005-05-20 2008-11-20 バイレクシス コーポレイション 初代細胞の形質導入
US8198045B2 (en) * 2006-04-19 2012-06-12 Biogenerix Ag Expression of O-glycosylated therapeutic proteins in prokaryotic microorganisms
EP3336174A1 (en) * 2006-06-02 2018-06-20 Robert Sackstein Compositions and methods for modifying cell surface glycans
WO2009020201A1 (ja) * 2007-08-08 2009-02-12 Kyowa Hakko Kirin Co., Ltd. 単離された細胞集団
JP5615509B2 (ja) * 2009-03-31 2014-10-29 北海道公立大学法人 札幌医科大学 フコシル化糖鎖産生細胞用物質送達担体
EP2480671B8 (en) * 2009-09-22 2015-10-28 ProBioGen AG Process for producing molecules containing specialized glycan structures
CA2954534C (en) * 2014-07-07 2023-04-04 Targazyme, Inc. Manufacture and cryopreservation of fucosylated cells for therapeutic use

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039104A1 (en) * 1996-04-17 1997-10-23 Osiris Therapeutics, Inc. Cryopreservation and extensive subculturing of human mesenchymal stem cells
US20050026133A1 (en) * 2002-01-31 2005-02-03 Asahi Techno Glass Corporation Cryopreservation medium for primate embryo stem cells and cryopreservation method
US20040209357A1 (en) * 2003-04-18 2004-10-21 Lijun Xia Hematopoietic stem cells treated by in vitro fucosylation and methods of use
WO2005017115A3 (en) * 2003-08-11 2005-06-02 Sinai School Medicine Cord blood-derived hematopoietic progenitor cells
US20110091434A1 (en) * 2008-06-09 2011-04-21 America Stem Cell, Inc. Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucosyltransferase
US20100304436A1 (en) * 2009-06-02 2010-12-02 Regeneron Pharmaceuticals, Inc. Fucosylation-Deficient Cells
US20100311036A1 (en) * 2009-06-09 2010-12-09 University Of South Carolina Methods for Augmentation of Cell Cryopreservation
US20110136682A1 (en) * 2009-12-04 2011-06-09 Momenta Pharmaceuticals, Inc. Antennary fucosylation in glycoproteins from cho cells
CN102648708A (zh) * 2011-02-25 2012-08-29 深圳华大方舟生物技术有限公司 一种用于胚胎或细胞的冷冻液及其用途

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AYATOLLAHI等: "Conditions to improve expansion of human mesenchymal stem cells based on rat samples", 《WORLD JOURNAL OF STEM CELLS》 *
K LEE等: "Developing in: fracture mechanics: twenty-third symposium", 《ASTM INTERNATIONAL》 *
RAFFAELLA GIANCOLA等: "Cell therapy: cGMP facilities and manufacturing", 《MUSCLES, LIGAMENTS AND TENDONS JOURNAL》 *
SHPALL E J等: "Novel cord blood transplant therapies", 《BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION》 *
刘建福: "《细胞工程》", 30 June 2014, 华中科学技术大学出版社 *
张永法: "《造血干细胞基础与临床》", 30 October 1995, 河南医科大学出版社 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114615886A (zh) * 2019-08-29 2022-06-10 得克萨斯大学体系董事会 细胞冷冻保存培养基
CN113521249A (zh) * 2020-04-14 2021-10-22 慈济学校财团法人慈济大学 动员干细胞的方法
US12188049B2 (en) 2020-04-14 2025-01-07 Tzu Chi University Methods for mobilizing stem cells
CN113521249B (zh) * 2020-04-14 2025-06-27 慈济学校财团法人慈济大学 动员干细胞的方法

Also Published As

Publication number Publication date
KR20170041204A (ko) 2017-04-14
CN114540266A (zh) 2022-05-27
JP7788486B2 (ja) 2025-12-18
EP3167046A4 (en) 2017-12-20
AU2015288052B2 (en) 2021-12-16
JP2017525340A (ja) 2017-09-07
US20230014609A1 (en) 2023-01-19
KR102505009B1 (ko) 2023-03-03
AU2015288052A1 (en) 2017-02-02
SG11201610699XA (en) 2017-01-27
CA2954534A1 (en) 2016-01-14
JP2024099565A (ja) 2024-07-25
US20190062694A1 (en) 2019-02-28
AU2022201639A1 (en) 2022-03-31
WO2016007506A1 (en) 2016-01-14
CA2954534C (en) 2023-04-04
EP3167046A1 (en) 2017-05-17
US20170121673A1 (en) 2017-05-04
JP2022065029A (ja) 2022-04-26

Similar Documents

Publication Publication Date Title
JP7788486B2 (ja) 治療的用途のためのフコシル化細胞の製造
Bieback et al. Mesenchymal stromal cells from umbilical cord blood
Bieback et al. Clinical protocols for the isolation and expansion of mesenchymal stromal cells
US20080241107A1 (en) Methods and Compositions For Preparing Pancreatic Insulin Secreting Cells
US8277794B2 (en) Immune privileged and modulatory progenitor cells
US20140205582A1 (en) Megakaryocyte progenitor cells for production of platelets
US20250297222A1 (en) Xeno-free generation of tissue-specific progenitor cells
Haylock et al. Expansion of umbilical cord blood for clinical transplantation
US20140193375A1 (en) Mesenchymal Stromal Cell Populations and Methods of Making Same
CN113557296A (zh) 造血干细胞的扩增
CA2632288A1 (en) Methods of improving stem cell homing and engraftment
Taghizadeh Perinatal mesenchymal stem cell banking for umbilical cord blood transplantation and regenerative medicine
菊地健志 et al. Study on methods of suppression of cell aggregation and utilization of pigs as cell source in mesenchymal stem cell therapy
Hosing et al. Mesenchymal stromal cells and umbilical cord blood transplantation
Mohammed Improvement and Comparison of Mesenchymal Stem Cell Cultivation from Umbilical Cord Using Different Concentrations of Fetal Bovine Serum and Platelets Lysate
Stewart Stem Cells and Stem Cell therapies: the Future for Regenerative Medicine?
Samuelsson Mesenchymal stromal/stem cells: expansion, engraftment and immune modulation
Blood Non-hematopoietic Stem and Progenitor Cells
Weiss et al. Mesenchymal Stromal Cells Derived from Wharton's Jelly
Congressi First International Workshop CELL THERAPY: FILLING THE GAP BETWEEN BASIC SCIENCE AND CLINICAL TRIALS

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20170517

RJ01 Rejection of invention patent application after publication